In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Every month ECDC provides detailed epidemiological overview of the worldwide transmission of chikungunya in its weekly threat report (Communicable Diseases Threat Report).
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season.